Competition for metabolic enzymes could theoretically alter the blood levels of either BPC-157 or the competing medication
Do not share it with another person
A phase I trial in advanced HCC has demonstrated that GPC3 peptide vaccine-induced GPC3-specific CTLs that could infiltrate into the HCC tissues, leading to improved OS induced by GPC3-based vaccine in advanced HCC (Tsuchiya et al., 2017)
[5] [7] At dosages exceeding 5 grams, there is a potential risk for more severe adverse effects, including renal dysfunction, blood toxicity, and neurological symptoms
Volpi, E., Nazemi, R., & Fujita, S
Zhao, Y., Vanhoutte, P